Dr. Melody G. Dumlao, MD

Dr. Dumlao practices at DaVita Delano Dialysis in Delano, California.

Dr. Dumlao's NPI, 1316938178, was assigned on November 2, 2005. Dr. Dumlao graduated from Manila Central University College of Medicine in 1992. Dr. Dumlao holds California license A74044.

Dr. Dumlao's primary practice is DaVita Delano Dialysis, at 405 Dover Parkway, Delano, CA 93215 in Kern County. The practice phone is (661) 725-1323.

Dr. Dumlao's primary practice is DaVita Delano Dialysis in Delano, California. Dr. Dumlao is also affiliated with Adventist Health Delano. The medical group on file is Central Kern Nephrology Medical Group. Dmand AI also links Dr. Dumlao to 4 more hospitals, 4 dialysis centers and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dumlao practices, 11 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Dumlao's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Dumlao is board certified in nephrology by the American Board of Internal Medicine. Dmand AI has Dr. Dumlao's licenses on file in 2 states: California and Illinois.

Dmand AI lists acute kidney failure, chronic anemia, chronic kidney disease, fluid and electrolyte imbalances, hypercalcemia and parathyroid gland disorder among the conditions Dr. Dumlao treats.

CMS data shows 3,124 Medicare services from Dr. Dumlao across 15 procedure codes in 2024, for 731 Medicare patients. Medicare paid $523,924 for them.

CMS counts 731 Medicare patients who saw Dr. Dumlao in 2024. The largest group is 65 to 74, with 241 patients. 75% of them have chronic kidney disease, and 75% have diabetes. 71% are also on Medicaid. Their average risk score is 5.56, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dumlao's median patient age at 67, with 45% women.

In 2024, Dr. Dumlao wrote 3,725 Medicare Part D claims for 415 patients. 81% of them were for generic drugs. CMS names the drug for 3,443 of them, across 61 drugs with 11 or more claims each, at $1,061,401 in total drug cost. In 2023, CMS named 2,978 claims across 60 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 98 out of 100 for Dr. Dumlao for performance year 2024, reported as part of a group. Dr. Dumlao accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dumlao as offering telehealth.

CMS Open Payments shows 14 general payments to Dr. Dumlao from 9 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 92% of the total. Relypsa, Inc. paid the most, $112.

Dmand AI lists 1 award for Dr. Dumlao, most recently CMS Stage 1 2012 in 2012.

Dr. Dumlao graduated from Manila Central University College of Medicine in 1992.

Dr. Dumlao is in network with 11 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.